CHPA To Lobby Against FDA-Initiated Rx-To-OTC Switches
This article was originally published in The Tan Sheet
Executive Summary
Congress should discourage FDA from pursuing Rx-to-OTC switches without the drug sponsor's approval, the Consumer Healthcare Products Association asserts
You may also be interested in...
CHPA Regulatory, Scientific Affairs To Be Headed By P&G’s Bierer
Procter & Gamble exec Douglas Bierer, PhD, will succeed 18-year Consumer Healthcare Products Association veteran William Soller, PhD, in leading the group's regulatory and scientific affairs department effective May 5
CHPA Regulatory, Scientific Affairs To Be Headed By P&G’s Bierer
Procter & Gamble exec Douglas Bierer, PhD, will succeed 18-year Consumer Healthcare Products Association veteran William Soller, PhD, in leading the group's regulatory and scientific affairs department effective May 5
CHPA Regulatory, Scientific Affairs To Be Headed By P&G’s Bierer
Procter & Gamble exec Douglas Bierer, PhD, will succeed 18-year Consumer Healthcare Products Association veteran William Soller, PhD, in leading the group's regulatory and scientific affairs department effective May 5